Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.
Novo Nordisk A/S CEO Lars Jørgensen said that US reimbursement for its rising star Wegovy (semaglutide) is ticking upwards, but that the results of a cardiovascular outcomes trial (CVOT) expected later this year, if successful, could better position the obesity drug for broader reimbursement, not only in the US, but in European markets.
Jørgensen outlined the current supply and market access position of Wegovy during an interview at the CNBC Health Returns conference,...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
